Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
564
resultados
Última actualización
21/03/2026 [07:58:00]
Resultados 200 a 225 de 564
Resumen de: US20260069698A1
The present invention provides prodrugs and methods of use thereof.
Resumen de: US20260069549A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Resumen de: US20260069542A1
The present invention provides cationic lipids and lipid nanoparticle formulations comprising these lipids, alone or in combination with other lipids. These lipid nanoparticles may be formulated with nucleic acids to facilitate their intracellular delivery both in vitro and for therapeutic applications. The present invention also provides methods of chemical synthesis of these lipids.
Resumen de: US20260069541A1
Disclosed herein are lipid nanoparticles for the delivery of active agents, including nucleic acids, as well as methods of making using thereof.
Resumen de: US20260069539A1
Compositions comprising lipidoid compounds, methods of preparing such compositions, and the use of these compositions in gene delivery applications are disclosed.
Resumen de: US20260069538A1
In various embodiments drug delivery vehicles and uses thereof are provided. In certain embodiments the drug delivery vehicles comprise: 1) a silicasome comprising a mesoporous silica nanoparticle coated with a lipid bilayer and further comprising a CXCR4 antagonist; or 2) a liposome comprising a lipid bilayer comprising where said liposome further comprises a CXCR4 antagonist. In certain embodiments the CXCR4 antagonists are selected from the group consisting of AMD3100, AMD3465, and AMD070.
Resumen de: US20260069540A1
Nanoparticle compositions for delivery of nucleic acids to subjects including aminoalkyl branched lipid-like molecules as carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the nanoparticle containing are described. Also provided are methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects.
Resumen de: US20260069536A1
The present disclosure provides compositions, systems, devices, and methods for the delivery of therapeutics. Particularly, the disclosure provides composition, systems, and devices of the delivery of Janus kinase (JAK) inhibitors and uses thereof, such as for inhibiting allograft rejection or treating autoimmune diseases.
Resumen de: US20260070960A1
Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.
Resumen de: WO2026055268A1
Methods of treating cancer, including RAS-mutated cancers and certain RAF-mutated cancers, are provided, comprising the administration of a therapeutically effective amount of dual-MEK inhibitor with a short plasma half-life that inhibits both the phosphorylation of mitogen-activated protein kinase kinase 1 or 2 (pMEK) and the phosphorylation of mitogen-activated protein kinase 1 or 2 (pERK), wherein the dual-MEK inhibitor is administered to the patient in certain dose amounts that achieves a Cmax effective to inhibit pERK and pMEK and with an interval between consecutive doses that is at least about certain times the plasma half-life of the dual-MEK inhibitor.
Resumen de: WO2026055102A1
A self-assembling composition includes molecules of a first polymer, molecules of a positively charged second polymer, and a nucleic add. First pendant groups conjugated to pendant amine group of the first polymer include a hydrophilic polymer. Second pendant groups conjugated to the pendant amine groups include a hydrophobic group. Third pendant groups conjugated to the pendant amine groups include a group selected from a nucleoside and a nucleoside analog. Fourth pendant groups conjugated to the second polymer via pendant amine groups thereof include the hydrophilic polymer. Fifth pendant groups are conjugated to the amine groups of the second polymer include the hydrophobic group. The second polymer also includes repeat units wherein the pendant amine groups are positively charged in vivo.
Resumen de: WO2026053150A1
The present disclosure provides pharmaceutical compositions, e.g., drug-containing nanocomposites, nanosuspensions thereof, and lyophilized powders thereof, that increase the apparent water solubility of hydrophobic active pharmaceutical ingredients and provide improved oral bioavailability and pharmacokinetic properties.
Resumen de: WO2026051763A1
Provided are a new gene drug delivery system based on a three-component lipid nanoparticle (LNP), and a preparation method therefor and the use thereof. The three-component LNP is composed of three ingredients: a cationic lipid, a structural lipid and a polymer-conjugated lipid. By means of precise ratio optimization, the three-component LNP maintains an efficient delivery performance while achieving component simplification. Compared with traditional four-component LNPs, the three-component LNP reduces the types of chemical components during preparation, thereby significantly reducing the complexity and cost of the production process, and making the three-component LNP more suitable for large-scale industrial production. In addition, due to the reduction in the types of components, the three-component LNP exhibits improved biocompatibility, reduced potential immunogenicity and toxicity risks, and higher safety.
Resumen de: WO2026051504A1
An optogenetic system promoting the targeted homing of MSCs to a damaged liver, and a preparation method therefor. On the basis that VUR8 exhibits a dimer structure in a natural state and dissociates following UVB irradiation, an optogenetic system comprising light-controlled CXCR4-releasing plasmids which contain UVR8 and CXCR4 sequences and upconversion nanoparticles which can convert NIR having strong tissue penetration capability into UVB is developed, and the optogenetic system is used for implementing the overexpression of CXCR4 only on MSC cells in the liver region so as to promote the targeted homing effect thereof.
Resumen de: WO2026052114A1
A lipid nanoparticle, comprising an ionizable lipid, a steroid compound and a polyethylene glycol-lipid, and not comprising a helper lipid. The ionizable lipid is selected from a compound having a structure represented by formula (I) and/or a pharmaceutically acceptable salt thereof. The three-component lipid nanoparticle not comprising a helper lipid reduces the complexity of the formulation and the difficulty of large-scale production, and further improves the nucleic acid encapsulation efficiency.
Resumen de: WO2026050896A1
Provided is a targeted nano-delivery kit comprising an active ingredient, a targeted guiding agent, and an optional delivery carrier and/or polymer, wherein the targeted guiding agent has the following characteristics: (1) it possesses a recognition group in its chemical structure; (2) the recognition group contains one or more of glycosyl groups of n-valent rhamnose, mannose, and galactose, and derivatives thereof; and (3) the recognition group is linked to an aglycone and/or other glycosyl groups of the targeted guiding agent by means of a covalent bond, where 1 ≤ n ≤ 10. The targeted nano-delivery kit has high drug loading and encapsulation efficiency, exhibits no intrinsic cytotoxicity, and can achieve multiple targeted deliveries. It improves the reliability of the delivery system while providing differentiated pharmacokinetic characteristics, reduces the systemic toxicity of undifferentiated system administration in the prior art, reduces first-pass metabolism, and thereby provides a safer, more reliable, and more effective treatment method.
Resumen de: WO2026050872A1
Provided herein are compositions for delivering a molecular cargo to a lung cell or tissue. The composition may include lipids such as a cationic lipid, a helper lipid, an ionizable lipid, a PEGylated lipid, or cholesterol. Some embodiments include a fusion-associated small transmembrane (FAST) polypeptide. Also provided are methods for using the compositions. The method may include delivering a molecular cargo to a lung cell or tissue.
Resumen de: WO2026050897A1
Provided is a stevioside derivative. The stevioside derivative is a compound represented by general formula Ia, or a salt thereof, or a hydrate thereof, or any mixture of the compound represented by general formula Ia, the salt thereof, and the hydrate thereof. In general formula Ia, R1 and R2 are independent of each other. R1 is selected from hydroxyl or glycosyl, and R2 is selected from n-valent rhamnose, rhamnopyranose, mannose, mannopyranose, galactose, galactopyranose, or combinations thereof, or oligosaccharides formed by means of covalent bonding with other sugars, wherein 1 ≤ n ≤ 10, for example, n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. The derivative or an in-vivo metabolite thereof has balanced hydrophilicity and lipophilicity and a multi-triggerable group and can serve as a delivery carrier and/or targeted guiding agent for an active ingredient. Further provided is a preparation method for the derivative and a use of the derivative.
Resumen de: US20260062688A1
A drug for genetic modification according to an embodiment is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule and a lipid nanoparticle encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol % or less, and the total amount of the cationic lipid is 60 mol % or less.
Resumen de: WO2026052854A1
The disclosure provides nanoparticle lipid compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) a sterol; and (c) a stabilizer. The disclosure provides methods for preparing the lipid nanoparticle compositions and uses of the lipid nanoparticle or the pharmaceutical composition for preventing, treating, or ameliorating conditions or diseases.
Resumen de: US20260070935A1
Described herein, in part, are bisphosphonate lipid compounds, lipid nanoparticles (LNPs) thereof, and methods of use thereof. In various embodiments, the LNP selectively targets a cell of interest (e.g., a bone cell and/or bone marrow cell, such as a stem cell, stroma cell, osteoblast, osteocyte, osteoclast, bone lining cell, local mesenchymal cell, progenitor cell, mononuclear blood-borne precursor cell, B cell, endothelial cell, granulocytes, T cell, monocytic lineage, B cell lineage, monocytes, cancer cell, tumor cell, tumor cell that metastasize to bone, blood cancer cell, and multiple myeloma cell, inter alia). In other aspects, the present disclosure relates to methods for in vivo delivery of therapeutic agents to prevent or treat diseases, disorders, or conditions using the LNP compositions of the disclosure.
Resumen de: US20260070964A1
The present disclosure relates to a combination therapy comprising an anti-VEGF antibody, a nanoparticle formulated plasmid comprising an IL-12 coding nucleic acid, and, optionally, at least one adjunctive chemotherapeutic drug, and methods of treatment using such combination therapies and/or compositions.
Resumen de: AU2026201122A1
Abstract The invention relates to biocompatible polysaccharide-based nanocapsule templated on oil core of diameter not exceeding 1 μm, stabilized without low molecular weight surfactants. The nanocapsule shows long-term stability in an aqueous suspension and is able to highly efficient encapsulation of hydrophobic compounds. Abstract eb b s t r a c t e b
Resumen de: US20260070985A1
Disclosed are nanoparticles comprising directionally attached antibodies and compositions for use in locoregional delivery, including intra-tumoral and transarterial chemoembolization (TACE), and methods of making the nanoparticles. Also disclosed are methods for treating a subject in need thereof the compositions described.
Nº publicación: AU2024367887A1 12/03/2026
Solicitante:
GREEN CROSS CORP
GREEN CROSS CORPORATION
Resumen de: AU2024367887A1
The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.
BOPI
Sede Electrónica
